Presbia PLC (NASDAQ: LENS) is one of 82 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its peers? We will compare Presbia PLC to similar businesses based on the strength of its earnings, dividends, analyst recommendations, risk, profitability, valuation and institutional ownership.

Earnings & Valuation

This table compares Presbia PLC and its peers top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Presbia PLC $13,000.00 -$16.76 million -2.57
Presbia PLC Competitors $2.02 billion $430.37 million -56.73

Presbia PLC’s peers have higher revenue and earnings than Presbia PLC. Presbia PLC is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of current recommendations for Presbia PLC and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Presbia PLC 0 0 3 0 3.00
Presbia PLC Competitors 416 2180 3387 122 2.53

Presbia PLC currently has a consensus target price of $12.00, indicating a potential upside of 288.35%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 21.10%. Given Presbia PLC’s stronger consensus rating and higher possible upside, research analysts clearly believe Presbia PLC is more favorable than its peers.


This table compares Presbia PLC and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Presbia PLC N/A -150.69% -124.10%
Presbia PLC Competitors -330.26% -33.54% -12.51%

Insider and Institutional Ownership

16.5% of Presbia PLC shares are held by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are held by institutional investors. 74.7% of Presbia PLC shares are held by company insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Presbia PLC has a beta of 0.09, suggesting that its share price is 91% less volatile than the S&P 500. Comparatively, Presbia PLC’s peers have a beta of 0.89, suggesting that their average share price is 11% less volatile than the S&P 500.


Presbia PLC peers beat Presbia PLC on 7 of the 12 factors compared.

About Presbia PLC

Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders.

Receive News & Ratings for Presbia PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Presbia PLC and related companies with's FREE daily email newsletter.